The incidence of Kawasaki disease using hospital admissions data for England 2006-2021

Odingo, Myron; Rutter, Megan; Bowley, Jonathan; Peach, Emily J.; Lanyon, Peter C.; Grainge, Matthew J.; Stillwell, Peter; McPhail, Sean; Bythell, Mary; Aston, Jeanette; Stevens, Sarah; McCormack, Rachael; Brogan, Paul; Pearce, Fiona A.

doi:10.1093/rheumatology/kead051

All Outputs (7)

Antibody response to four doses of SARS-CoV-2 vaccine in rare autoimmune rheumatic diseases: an observational study (2023)
Journal Article
Gumber, L., Jackson, H., Gomez, N., Hopkins, G., Tucis, D., Chakravorty, M., …Fairclough, L. (2023). Antibody response to four doses of SARS-CoV-2 vaccine in rare autoimmune rheumatic diseases: an observational study. Rheumatology Advances in Practice, 7(3), Article rkad097. https://doi.org/10.1093/rap/rkad097

Objective Antibody response to COVID-19 vaccines are reduced among immunocompromised patients but are not well-quantified among people with rare disease. We conducted an observational study to evaluate the antibody responses to the booster SARS-CoV-... Read More about Antibody response to four doses of SARS-CoV-2 vaccine in rare autoimmune rheumatic diseases: an observational study.

Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies (2023)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., …Williams, H. C. (in press). Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, Article ljad430. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base supporting the use of six-monthly monitoring blood tests for the early detection of liver, blood, and renal toxicity during established anti-TNF-alpha treatment. Objectives: To evaluate the incidence... Read More about Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies.

Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation (2023)
Journal Article
Nakafero, G., Card, T., Grainge, M. J., Williams, H. C., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64, Article 102213. https://doi.org/10.1016/j.eclinm.2023.102213

Background: Patients established on thiopurines (e.g., azathioprine) are recommended to undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity. These side-effects are uncommon during long-term treatment. We deve... Read More about Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation.

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK (2023)
Journal Article
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381, Article e074678. https://doi.org/10.1136/bmj-2022-074678

OBJECTIVE: To develop and validate a prognostic model to inform risk stratified decisions on frequency of monitoring blood tests during long term methotrexate treatment. DESIGN: Retrospective cohort study. SETTING: Electronic health records within th... Read More about Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.

COVID-19 infection, admission and death and the impact of corticosteroids amongst people with rare autoimmune rheumatic disease during the second wave of covid-19 in England: results from the RECORDER Project (2023)
Journal Article
Rutter, M., Lanyon, P. C., Grainge, M. J., Hubbard, R., Bythell, M., Stilwell, P., …Pearce, F. A. (2023). COVID-19 infection, admission and death and the impact of corticosteroids amongst people with rare autoimmune rheumatic disease during the second wave of covid-19 in England: results from the RECORDER Project. Rheumatology, 62(12), 3828-3837. https://doi.org/10.1093/rheumatology/kead150

Objectives To calculate the rates of COVID-19 infection and COVID-19-related death among people with rare autoimmune rheumatic diseases (RAIRD) during the second wave of the COVID-19 pandemic in England, and describe the impact of corticosteroids on... Read More about COVID-19 infection, admission and death and the impact of corticosteroids amongst people with rare autoimmune rheumatic disease during the second wave of covid-19 in England: results from the RECORDER Project.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.

The incidence of Kawasaki disease using hospital admissions data for England 2006-2021 (2023)
Journal Article
Odingo, M., Rutter, M., Bowley, J., Peach, E. J., Lanyon, P. C., Grainge, M. J., …Pearce, F. A. (2023). The incidence of Kawasaki disease using hospital admissions data for England 2006-2021. Rheumatology, 62(9), 3117–3125. https://doi.org/10.1093/rheumatology/kead051

Objective: To describe the incidence of Kawasaki Disease (kDa) between 2006 and 2021 in England. Methods: We identified all cases in hospital episode statistics with an ICD-10 diagnostic code M303 (for kDa) between 1 April 2006 and 31 March 2021. We... Read More about The incidence of Kawasaki disease using hospital admissions data for England 2006-2021.